Literature DB >> 23990444

MicroRNA and transcription factor mediated regulatory network for ovarian cancer: regulatory network of ovarian cancer.

Huanchun Ying1, Jing Lv, Tianshu Ying, Jun Li, Qing Yang, Yuan Ma.   

Abstract

A better understanding on the regulatory interactions of microRNA (miRNA) target genes and transcription factor (TF) target genes in ovarian cancer may be conducive for developing early diagnosis strategy. Thus, gene expression data and miRNA expression data were downloaded from The Cancer Genome Atlas in this study. Differentially expressed genes and miRNAs were selected out with t test, and Gene Ontology enrichment analysis was performed with DAVID tools. Regulatory interactions were retrieved from miRTarBase, TRED, and TRANSFAC, and then networks for miRNA target genes and TF target genes were constructed to globally present the mechanisms. As a result, a total of 1,939 differentially expressed genes were identified, and they were enriched in 28 functions, among which cell cycle was affected to the most degree. Besides, 213 differentially expressed miRNAs were identified. Two regulatory networks for miRNA target genes and TF target genes were established and then both were combined, in which E2F transcription factor 1, cyclin-dependent kinase inhibitor 1A, cyclin E1, and miR-16 were the hub genes. These genes may be potential biomarkers for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23990444     DOI: 10.1007/s13277-013-0892-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  37 in total

1.  MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma.

Authors:  Johan H Gibcus; Bart-Jan Kroesen; Roelof Koster; Nancy Halsema; Debora de Jong; Steven de Jong; Sibrand Poppema; Joost Kluiver; Arjan Diepstra; Anke van den Berg
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

2.  The transcription factors signal transducer and activator of transcription 5A (STAT5A) and STAT5B negatively regulate cell proliferation through the activation of cyclin-dependent kinase inhibitor 2b (Cdkn2b) and Cdkn1a expression.

Authors:  Ji Hoon Yu; Bing-Mei Zhu; Mark Wickre; Gregory Riedlinger; Weiping Chen; Atsushi Hosui; Gertraud W Robinson; Lothar Hennighausen
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

3.  New functional activities for the p21 family of CDK inhibitors.

Authors:  J LaBaer; M D Garrett; L F Stevenson; J M Slingerland; C Sandhu; H S Chou; A Fattaey; E Harlow
Journal:  Genes Dev       Date:  1997-04-01       Impact factor: 11.361

4.  Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.

Authors:  S Cariou; J C Donovan; W M Flanagan; A Milic; N Bhattacharya; J M Slingerland
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

5.  Regulation of the cyclin E gene by transcription factor E2F1.

Authors:  K Ohtani; J DeGregori; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

6.  Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells.

Authors:  Fu Wang; Xiang-Dong Fu; Yu Zhou; Yi Zhang
Journal:  BMB Rep       Date:  2009-11-30       Impact factor: 4.778

7.  Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation.

Authors:  Lijian Hui; Kurt Zatloukal; Harald Scheuch; Ewa Stepniak; Erwin F Wagner
Journal:  J Clin Invest       Date:  2008-11-06       Impact factor: 14.808

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC.

Authors:  Hans-Ingo Trompeter; Hassane Abbad; Katharina M Iwaniuk; Markus Hafner; Neil Renwick; Thomas Tuschl; Jessica Schira; Hans Werner Müller; Peter Wernet
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

10.  Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells.

Authors:  Blanca L Valle; Theresa D'Souza; Kevin G Becker; William H Wood; Yongqing Zhang; Robert P Wersto; Patrice J Morin
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

View more
  4 in total

1.  Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer.

Authors:  Ling Liu; Jing Zou; Qi Wang; Fu-Qiang Yin; Wei Zhang; Li Li
Journal:  Tumour Biol       Date:  2014-05-08

2.  Circulating microRNAs in esophageal squamous cell carcinoma: association with locoregional staging and survival.

Authors:  Bing-Xin Li; Qi Yu; Ze-Liang Shi; Ping Li; Shen Fu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

3.  NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis.

Authors:  Changxian Chen; Yanling Hu; Li Li
Journal:  Mol Med Rep       Date:  2015-11-11       Impact factor: 2.952

4.  MicroRNA-transcription factor network analysis reveals miRNAs cooperatively suppress RORA in oral squamous cell carcinoma.

Authors:  Xueqing Zheng; Kejing Wu; Shengjie Liao; Yuemei Pan; Yanan Sun; Xinming Chen; Yi Zhang; Shu Xia; Yaying Hu; Jiali Zhang
Journal:  Oncogenesis       Date:  2018-10-08       Impact factor: 7.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.